Daily Edition · Page 2

THE DAILY INDEX

Technology, AI, software, security, crypto and business

MISCELLANEOUS

TLDR

WHAT IF OZEMPIC IS JUST A GOOD THING?

The public discussion of Ozempic's economics has so far been consistently fatalistic. Many doubt that the drug will benefit more than just the lucky few who can afford it. The people who most need the drug often struggle to get it. As long as it is talked about primarily as a weight loss drug, insurance companies will remain incentivized to treat it as a luxury good. The drug presents a radical opportunity to change the chronic disease landscape in the US, but it may require radical policy changes to make it accessible.

TLDR IndexPage 2